BRPI0607769A2 - pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais - Google Patents

pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais

Info

Publication number
BRPI0607769A2
BRPI0607769A2 BRPI0607769-2A BRPI0607769A BRPI0607769A2 BR PI0607769 A2 BRPI0607769 A2 BR PI0607769A2 BR PI0607769 A BRPI0607769 A BR PI0607769A BR PI0607769 A2 BRPI0607769 A2 BR PI0607769A2
Authority
BR
Brazil
Prior art keywords
viral infections
treatment
tricyclic
nucleoside
prodrugs
Prior art date
Application number
BRPI0607769-2A
Other languages
English (en)
Inventor
Jesse D Keicher
Christopher Don Roberts
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of BRPI0607769A2 publication Critical patent/BRPI0607769A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PRó-FáRMACOS NUCLEOSìDEO-TRICìCLICOS PARA TRATAMENTO DE INFECçõES VIRAIS. Esta invenção é direcionada a novos compostos que São úteis nas infecções virais em mamíferos, mediadas, pelo menos em parte, por um vírus da família de vírus Flaviviridae. Em um dos aspectos da composição, a presente invenção é direcionada aos compostos de Fórmula (I).
BRPI0607769-2A 2005-02-28 2006-02-28 pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais BRPI0607769A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65746305P 2005-02-28 2005-02-28
PCT/US2006/007131 WO2006093986A1 (en) 2005-02-28 2006-02-28 Tricyclic-nucleoside prodrugs for treating viral infections

Publications (1)

Publication Number Publication Date
BRPI0607769A2 true BRPI0607769A2 (pt) 2009-10-06

Family

ID=36570903

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0607770-6A BRPI0607770A2 (pt) 2005-02-28 2006-02-28 compostos de nucleosideo tricìclico para tratamento de infecções virais
BRPI0607769-2A BRPI0607769A2 (pt) 2005-02-28 2006-02-28 pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0607770-6A BRPI0607770A2 (pt) 2005-02-28 2006-02-28 compostos de nucleosideo tricìclico para tratamento de infecções virais

Country Status (18)

Country Link
US (4) US7524825B2 (pt)
EP (2) EP1853618A1 (pt)
JP (2) JP2008531704A (pt)
KR (2) KR20070106781A (pt)
CN (2) CN101142226A (pt)
AP (2) AP2007004118A0 (pt)
AR (1) AR058419A1 (pt)
AU (2) AU2006218704A1 (pt)
BR (2) BRPI0607770A2 (pt)
CA (2) CA2597685A1 (pt)
EA (2) EA200701850A1 (pt)
HR (2) HRP20070436A2 (pt)
IL (2) IL184955A0 (pt)
MX (2) MX2007010463A (pt)
NO (2) NO20074613L (pt)
TW (1) TW200640474A (pt)
WO (2) WO2006093986A1 (pt)
ZA (1) ZA200707410B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546055A (en) 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
AR058419A1 (es) * 2005-02-28 2008-02-06 Gilead Sciences Inc Compuestos de nucleosidos triciclicos para tratar infecciones virales
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
JP2010520200A (ja) 2007-02-28 2010-06-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド 特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
GB0718575D0 (en) * 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
GB2471806B (en) * 2008-04-03 2012-12-19 Spring Bank Pharmaceuticals Inc Compositions and methods for treating viral infections
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
GB0900914D0 (en) * 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
EP2414359A1 (en) * 2009-03-31 2012-02-08 ArQule, Inc. Peri-fused pyrazolo-pyrimidine compounds
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
JP2014520772A (ja) 2011-06-30 2014-08-25 ステラ・アンパルトセルスカブ Ｈｃｖ併用療法
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2639238A1 (en) * 2012-03-15 2013-09-18 Universität Bern Tricyclic nucleosides and oligomeric compounds prepared therefrom
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DE69133402T2 (de) 1990-04-04 2004-11-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Protease von hepatitis-c-virus
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69434931T2 (de) 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
WO1997012033A1 (en) 1995-09-27 1997-04-03 Emory University Recombinant hepatitis c virus rna replicase
US5759795A (en) * 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
CA2283379A1 (en) 1997-03-05 1998-09-11 Michael G. Katze Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
EP0973788A1 (en) 1997-04-02 2000-01-26 Amersham Pharmacia Biotech UK Limited Tricyclic base analogues
CA2312484A1 (en) 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SK286630B6 (sk) * 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
WO2003061385A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
NZ546055A (en) * 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
US7144868B2 (en) * 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CA2542776A1 (en) * 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
AR058419A1 (es) 2005-02-28 2008-02-06 Gilead Sciences Inc Compuestos de nucleosidos triciclicos para tratar infecciones virales

Also Published As

Publication number Publication date
KR20070106781A (ko) 2007-11-05
NO20074613L (no) 2007-11-27
MX2007010463A (es) 2007-11-08
IL184954A0 (en) 2007-12-03
CA2597683A1 (en) 2006-09-08
CN101128474A (zh) 2008-02-20
HRP20070435A2 (hr) 2008-02-29
JP2008531704A (ja) 2008-08-14
MX2007010460A (es) 2007-11-08
US7534771B2 (en) 2009-05-19
JP2008531703A (ja) 2008-08-14
IL184955A0 (en) 2007-12-03
AU2006218705A1 (en) 2006-09-08
WO2006093987A1 (en) 2006-09-08
KR20070106767A (ko) 2007-11-05
EP1853617A1 (en) 2007-11-14
AP2007004128A0 (en) 2007-08-31
US7524825B2 (en) 2009-04-28
TW200640474A (en) 2006-12-01
ZA200707410B (en) 2008-10-29
NO20074915L (no) 2007-11-20
US20060252715A1 (en) 2006-11-09
BRPI0607770A2 (pt) 2009-06-13
US20060194749A1 (en) 2006-08-31
AP2007004118A0 (en) 2007-08-31
CN101142226A (zh) 2008-03-12
WO2006093986A1 (en) 2006-09-08
EP1853618A1 (en) 2007-11-14
EA200701850A1 (ru) 2008-02-28
HRP20070435A9 (en) 2008-09-30
AU2006218704A1 (en) 2006-09-08
HRP20070436A2 (hr) 2008-02-29
CA2597685A1 (en) 2006-09-08
EA200701849A1 (ru) 2008-02-28
US20090208457A1 (en) 2009-08-20
US20090253648A1 (en) 2009-10-08
AR058419A1 (es) 2008-02-06

Similar Documents

Publication Publication Date Title
BRPI0607769A2 (pt) pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais
BR112012008533A2 (pt) combinações de inibidores do vírus de hepatite c
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
BR112014017266A2 (pt) inibidores de vírus da hepatite c
ECSP13010937A (es) Compuestos antivirales
TNSN07252A1 (en) Indole derivatives for treating viral infections
TW200720285A (en) Nucleoside compounds for treating viral infections
NI200900069A (es) Inhibidores de la proteasa ns3 del hcv
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
BRPI0720569B8 (pt) compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária
WO2012092484A3 (en) Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
GT200600327A (es) Ciclohexilaminoisoquinolona
BR112013020042A2 (pt) inibidores de vírus da hepatite c
WO2007120374A3 (en) Anti-arenaviral compounds
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112013032049A2 (pt) inibidores do vírus da hepatite c
WO2008008907A3 (en) Antiviral agents
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
MX2009008495A (es) Novedosos analogos de nucleosidos para el tratamiento de infecciones virales.
WO2008011521A3 (en) Polycyclic viral inhibitors
BR112014015582A2 (pt) compostos antivirais
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.